Advertisement

Topics

Global Blood Therapeutics' once-a-day pill for sickle cell disease boosted levels of oxygen-carrying hemoglobin in more than half of the patients treated in a Phase 3 clinical trial, but questions about patient benefit still linger. https://buff.ly/2IOaCO

20:00 EDT 14 Jun 2019 | STAT

Global Blood Therapeutics' once-a-day pill for sickle cell disease boosted levels of oxygen-carrying hemoglobin in more than half of the patients treated in a Phase 3 clinical trial, but questions about patient benefit still linger. https://buff.ly/2IOaCOO 

Original Article: Global Blood Therapeutics' once-a-day pill for sickle cell disease boosted levels of oxygen-carrying hemoglobin in more than half of the patients treated in a Phase 3 clinical trial, but questions about patient benefit still linger. https://buff.ly/2IOaCO

NEXT ARTICLE

More From BioPortfolio on "Global Blood Therapeutics' once-a-day pill for sickle cell disease boosted levels of oxygen-carrying hemoglobin in more than half of the patients treated in a Phase 3 clinical trial, but questions about patient benefit still linger. https://buff.ly/2IOaCO"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...